Comments on “Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical …

EG Favalli, F Conti, F Atzeni, C Selmi… - Journal of the American …, 2018 - jaad.org
Baseline characteristics Female, n (%) 83 (63.3) 92 (54.8) 95 (58.6) 88 (53) 275 (55.3). 11
Mean age, y (SD) 57.5 (12) 51.4 (11.7) 50.5 (11.2) 49.9 (11.4) 50.6 (11.4) Mean duration of …
被引用次数：2 相关文章

[引用][C] Comments on “Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in …

EG Favalli, F Conti, F Atzeni, C Selmi… - JOURNAL OF THE …, 2018 - iris.hunimed.eu
Comments on “Short-term reasons for withdrawal and adverse events associated with
apremilast therapy for psoriasis in real-world practice compared with in clinical trials : a …
[PDF] unimi.it

[PDF][PDF] Comments on “Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in …

EG Favalli, F Conti, F Atzeni, C Selmi… - JOURNAL OF THE …, 2018 - air.unimi.it
Baseline characteristics Female, n (%) 83 (63.3) 92 (54.8) 95 (58.6) 88 (53) 275 (55.3). 11
Mean age, y (SD) 57.5 (12) 51.4 (11.7) 50.5 (11.2) 49.9 (11.4) 50.6 (11.4) Mean duration of …

[引用][C] Comments on" Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in …

EG Favalli, F Conti, F Atzeni, C Selmi… - Journal of the …, 2018 - europepmc.org
Comments on "Short-term reasons for withdrawal and adverse events associated with
apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A …

[引用][C] Comments on ''Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in …

E Favalli, F Conti, F Atzeni, C Selmi… - JOURNAL OF THE …, 2018 - iris.unime.it
Comments on ‘‘Short-term reasons for withdrawal and adverse events associated with
apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A …

[引用][C] Comments on “Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in …

EG Favalli, F Conti, F Atzeni, C Selmi… - JOURNAL OF THE …, 2018 - ricerca.uniba.it
Comments on “Short-term reasons for withdrawal and adverse events associated with apremilast
therapy for psoriasis in real-world practice compared with in clinical trials: A multicenter …

[引用][C] Comments on" Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in …

EG Favalli, F Conti, F Atzeni, C Selmi… - Journal of the …, 2018 - pubmed.ncbi.nlm.nih.gov
Comments on "Short-term reasons for withdrawal and adverse events associated with apremilast
therapy for psoriasis in real-world practice compared with in clinical trials: A multicenter …
[PDF] unimi.it

[PDF][PDF] Table I. Baseline characteristics and safety profile of apremilast population included in RCTs and in the RAPPER cohort

Depression - air.unimi.it
Baseline characteristics Female, n (%) 83 (63.3) 92 (54.8) 95 (58.6) 88 (53) 275 (55.3). 11
Mean age, y (SD) 57.5 (12) 51.4 (11.7) 50.5 (11.2) 49.9 (11.4) 50.6 (11.4) Mean duration of …